Zealand Pharma's Upcoming Conference Call
Zealand Pharma A/S, a prominent biotechnology firm known for its innovative peptide-based medicines, has announced an important event on August 14, 2025. The company will hold a conference call at 2:00 PM CET, equivalent to 8:00 AM ET, to discuss its financial results for the second quarter of 2025.
Key Participants in the Call
The conference call will feature a lineup of executive members from Zealand Pharma. This includes Adam Steensberg, the President and Chief Executive Officer; Henriette Wennicke, the Chief Financial Officer; David Kendall, the Chief Medical Officer; and Eric Cox, the Chief Commercial Officer. Each participant brings a wealth of knowledge and expertise that will surely provide valuable insights into the company’s performance and growth strategies.
How to Participate in the Conference Call
For those interested in tuning into the call, a live audio webcast will be provided alongside a presentation that can be accessed through Zealand Pharma's investor relations section. It is advised to register for the call or the webcast at least 10 minutes before the commencement time for a seamless experience.
Accessing the Event Recording
After the call, a recording will be accessible on Zealand Pharma’s website, ensuring that anyone unable to join live can still catch up on the discussions and insights shared during the event.
About Zealand Pharma A/S
Founded in 1998, Zealand Pharma A/S has established itself as a leader in the biotechnology sector. With an impressive portfolio of over ten drug candidates in clinical development, the company has successfully brought two of these candidates to market, while three additional ones are in advanced stages of development. Zealand Pharma actively collaborates with various pharmaceutical companies, bolstering its commitment to developing high-quality peptide-based medicines.
Company's Growth and Future Outlook
Zealand Pharma's continuous innovation and strategic partnerships reflect its firm commitment to advancing medical science and providing effective treatment solutions. The company is not only focused on present outcomes but is also strategizing for a sustainable and productive future in the dynamic biotechnology landscape.
Company Contacts for Additional Information
For further inquiries regarding Zealand Pharma, interested parties can reach out to the following contacts:
Adam Lange (Investors)
Vice President, Investor Relations
Email: alange@zealandpharma.com
Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Anna Krassowska, PhD (Investor and Media)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com
Frequently Asked Questions
What is the purpose of the Zealand Pharma conference call?
The call is intended to present the company's financial results for Q2 2025 and discuss future strategies.
Who will be speaking during the conference call?
The call will feature key executives including the CEO, CFO, CMO, and CCO.
How can I listen to the conference call?
Participants can join by accessing a live audio webcast available on Zealand Pharma’s website.
Will there be a recording of the call available?
Yes, a recording will be available on the company's website after the event concludes.
What is Zealand Pharma's main focus?
Zealand Pharma specializes in the discovery and development of innovative peptide-based medicines.
